title: Interleukin-1 receptor-related protein ST2 suppresses the initial stage of bleomycin-induced lung injury.
abstract: Acute lung injury has a range of causes, and occasionally leads to lethal respiratory failure. Despite advances in treatment, acute lung injury continues to have a high mortality rate, and thus a new therapeutic approach is needed. ST2 is an interleukin (IL)-1 receptor-related protein, and its expression is induced by various inflammatory responses. Recently, ST2 has been speculated to exert anti-inflammatory effects; therefore, we investigated the role of the ST2 in the murine model of acute lung injury. To elucidate the function of ST2 in vivo, mice that transiently overexpressed ST2 protein were prepared using the hydrodynamic gene transfer method, and lung injury was induced by intratracheal administration of bleomycin. In bleomycin-treated ST2-overexpressing mice, the increase of neutrophils in the bronchoalveolar lavage fluid (BALF) was markedly suppressed. Additionally, the levels of tumour necrosis factor-alpha and IL-6, as well as the concentration of albumin, in BALF were reduced compared with those of controls. Furthermore, the pulmonary architecture in ST2-overexpressing mice remained almost normal, and the survival rate was significantly improved. From these results, we concluded that ST2 has the potential to suppress the initial stage of acute lung injury, and therefore it may be a useful reagent for the treatment of acute lung injury.
authors.affiliation: Dept of Medicine, Division of Pulmonary Medicine, Jichi Medical University, Shimotsuke-Shi, Tochigi , Japan.
authors.forename: N
authors.initials: N
authors.lastname: Mato
authors.forename: M
authors.initials: M
authors.lastname: Fujii
authors.forename: Y
authors.initials: Y
authors.lastname: Hakamata
authors.forename: E
authors.initials: E
authors.lastname: Kobayashi
authors.forename: A
authors.initials: A
authors.lastname: Sato
authors.forename: M
authors.initials: M
authors.lastname: Hayakawa
authors.forename: H
authors.initials: H
authors.lastname: Ohto-Ozaki
authors.forename: M
authors.initials: M
authors.lastname: Bando
authors.forename: S
authors.initials: S
authors.lastname: Ohno
authors.forename: S
authors.initials: S
authors.lastname: Tominaga
authors.forename: Y
authors.initials: Y
authors.lastname: Sugiyama
mesh_terms: D055371:Acute Lung Injury / Q000139:chemically induced / Q000188:drug therapy / Q000503:physiopathology*; D000418:Albumins / Q000378:metabolism; D000704:Analysis of Variance; D000818:Animals; D001761:Bleomycin / Q000633:toxicity; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry; D004797:Enzyme-Linked Immunosorbent Assay; D015870:Gene Expression; D018014:Gene Transfer Techniques; D005822:Genetic Vectors; D007375:Interleukin-1 / Q000378:metabolism; D000072179:Interleukin-1 Receptor-Like 1 Protein; D000067596:Interleukin-33; D015850:Interleukin-6 / Q000378:metabolism; D007378:Interleukins / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D010957:Plasmids; D018123:Receptors, Interleukin / Q000502:physiology*; D017472:Receptors, Interleukin-1 / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D001616:beta-Galactosidase / Q000378:metabolism
chemical_list: D000418:Albumins; C486189:Il1rl1 protein, mouse; C506535:Il33 protein, mouse; D007375:Interleukin-1; D000072179:Interleukin-1 Receptor-Like 1 Protein; D000067596:Interleukin-33; D015850:Interleukin-6; D007378:Interleukins; D018123:Receptors, Interleukin; D017472:Receptors, Interleukin-1; D014409:Tumor Necrosis Factor-alpha; D001761:Bleomycin; D001616:beta-Galactosidase